Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3466
Fax+1 617-632-2165
Dr. Xu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Wenxin Xu is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. He received his medical degree from Harvard Medical School and completed residency and fellowship training at Beth Israel Deaconess Medical Center. He specializes in genitourinary oncology.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2014 - 2017
Harvard Medical SchoolClass of 2014
Certifications & Licensure
NH State Medical License 2022 - 2026
MA State Medical License 2018 - 2025
ME State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award Conquer Cancer Foundation, 2020
Publications & Presentations
PubMed
- A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.Axel Bex, Michael Jewett, Bryan Lewis, E Jason Abel, Laurence Albiges
European Urology. 2025-04-01 - CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma.Bradley A McGregor, Wanling Xie, Stephanie A Berg, Wenxin Xu, Srinivas R Viswanathan
Clinical Genitourinary Cancer. 2025-02-18 - 1 citationsShareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research.Kenneth L Kehl, Justin Jee, Karl Pichotta, Morgan A Paul, Pavel Trukhanov
Nature Communications. 2024-11-12
Press Mentions
Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers SymposiumFebruary 11th, 2025- OncoHost Announces New Study on Biomarkers for Renal Cell CarcinomaJune 3rd, 2024
- Dana-Farber Cancer Institute and OncoHost Partner for Renal Cell Carcinoma ResearchJune 13th, 2024
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
